Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab after cyclophosphamide + doxorubicin induction in previously treated advanced non-squamous non-small cell lung cancer with PD-L1 <10%
KCT0003455Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Ono Pharmaceutical. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on KCT0003455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003455.